Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CCR8 monoclonal antibody AMG 355

A monoclonal antibody directed against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody AMG 355 targets and binds to CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	AMG 355 AMG-355 AMG355

anti-CCR8 monoclonal antibody AMG 355

Search NCI's Drug Dictionary